Elafibranor, PPARalpha/delta agonist (TBI3901)

Description

Product Details

Formal Name: 2-[2,6-Dimethyl-4-[(E)-3-(4-methylsulfanylphenyl)-3-oxoprop-1-enyl]phenoxy]-2-methylpropanoic acid

Alternate Names: GFT505

Molecular Formula: C₂₂H₂₄O₄S

Formula Weight: 384.50

CAS Number: 923978-27-2

Purity: >98%

Formulation: powder

Solubility: Soluble in DMSO (up to at least 25 mg/ml)

Storage: -20°C

Stability: ≥ 1 year.

 

Applications

PPARalpha/delta agonist

 

Functions

Elafibranor is a dual PPARalpha/delta agonist (EC50 PPARalpha = 10-20 nM; PPARdelta = 100-150 nM). It was able to decrease plasma triglycerides levels, increase HDL cholesterol levels in human studies, and improve hepatic and peripheral insulin sensitivity. Elafibranor’s antidiabetic effects in db/db were without the adverse cardiac effects seen in PPARgamma agonism. Elafibranor has also been shown to have therapeutic promise in the treatment of nonalcoholic steatohepatitis (NASH).

 

Application Procedures

First dissolved in DMSO (up to at least 25 mg/ml), then diluted to aqueous buffer. Solutions in DMSO may be stored at -20° for up to 1 month.

Additional information

SIZE (mg)	25 MG, 5 MG

Datasheet:

TBI3901_Elafibranor

MSDS:

TBI3901_Elafibranor_MSDS_2024